C. Dureau‐Pournin

455 total citations
28 papers, 336 citations indexed

About

C. Dureau‐Pournin is a scholar working on Cardiology and Cardiovascular Medicine, Economics and Econometrics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, C. Dureau‐Pournin has authored 28 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cardiology and Cardiovascular Medicine, 6 papers in Economics and Econometrics and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in C. Dureau‐Pournin's work include Atrial Fibrillation Management and Outcomes (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). C. Dureau‐Pournin is often cited by papers focused on Atrial Fibrillation Management and Outcomes (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). C. Dureau‐Pournin collaborates with scholars based in France, Netherlands and United Kingdom. C. Dureau‐Pournin's co-authors include R. Lassalle, Nicholas Moore, Patrick Blin, C. Droz‐Perroteau, Abdelilah Abouelfath, Alexandre Pariente, Jérémy Jové, Annie Fourrier‐Réglat, Marie‐Agnès Bernard and H. Gin and has published in prestigious journals such as European Heart Journal, Diabetologia and Clinical Pharmacology & Therapeutics.

In The Last Decade

C. Dureau‐Pournin

26 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Dureau‐Pournin France 10 109 51 43 38 34 28 336
Xiaoyang Liao China 12 87 0.8× 50 1.0× 71 1.7× 25 0.7× 19 0.6× 69 483
Natsumi Ueda Japan 13 59 0.5× 26 0.5× 37 0.9× 9 0.2× 43 1.3× 24 468
Siin Kim South Korea 8 47 0.4× 29 0.6× 33 0.8× 52 1.4× 26 0.8× 28 293
Ryogo Umetsu Japan 13 49 0.4× 22 0.4× 42 1.0× 10 0.3× 44 1.3× 21 467
Luis Carlos Saiz Spain 12 124 1.1× 56 1.1× 38 0.9× 11 0.3× 26 0.8× 40 386
Simone Y. Loo Canada 7 214 2.0× 46 0.9× 11 0.3× 15 0.4× 24 0.7× 7 399
Yamato Kato Japan 13 48 0.4× 18 0.4× 33 0.8× 9 0.2× 41 1.2× 25 423
Michele A. Faulkner United States 12 82 0.8× 27 0.5× 63 1.5× 41 1.1× 104 3.1× 41 524
RL Sacco United States 5 123 1.1× 79 1.5× 23 0.5× 83 2.2× 29 0.9× 5 586
D Schröder-Bernhardi Germany 9 85 0.8× 103 2.0× 34 0.8× 8 0.2× 59 1.7× 19 442

Countries citing papers authored by C. Dureau‐Pournin

Since Specialization
Citations

This map shows the geographic impact of C. Dureau‐Pournin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Dureau‐Pournin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Dureau‐Pournin more than expected).

Fields of papers citing papers by C. Dureau‐Pournin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Dureau‐Pournin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Dureau‐Pournin. The network helps show where C. Dureau‐Pournin may publish in the future.

Co-authorship network of co-authors of C. Dureau‐Pournin

This figure shows the co-authorship network connecting the top 25 collaborators of C. Dureau‐Pournin. A scholar is included among the top collaborators of C. Dureau‐Pournin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Dureau‐Pournin. C. Dureau‐Pournin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Luxi, Nicoletta, Luca L’Abbate, Florence van Hunsel, et al.. (2024). Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study. Vaccines. 12(3). 241–241. 3 indexed citations
3.
Hunsel, Florence van, Nicolas H. Thurin, C. Dureau‐Pournin, et al.. (2023). Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose. Drug Safety. 46(4). 391–404. 14 indexed citations
4.
Blin, Patrick, N Danchin, C. Dureau‐Pournin, et al.. (2022). Should dual antiplatelet therapy be maintained beyond one year after a myocardial infarction? A cohort study within the French SNDS nationwide claims database. European Heart Journal. 43(Supplement_2).
5.
Aubin, Henri‐Jean, C. Dureau‐Pournin, Bruno Falissard, et al.. (2021). Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis. Alcohol and Alcoholism. 56(5). 545–555. 3 indexed citations
6.
7.
8.
Droz‐Perroteau, C., Patrick Blin, C. Dureau‐Pournin, et al.. (2019). Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI. Therapies. 74(4). 459–468. 5 indexed citations
9.
Blin, Patrick, C. Dureau‐Pournin, Jacques Bénichou, et al.. (2019). Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS. American Journal of Cardiovascular Drugs. 20(1). 81–103. 8 indexed citations
10.
Blin, Patrick, C. Dureau‐Pournin, Jacques Bénichou, et al.. (2018). Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Atherosclerosis. 281. 98–106. 11 indexed citations
11.
Pariente, Alexandre, Anne Bénard‐Laribière, R. Lassalle, et al.. (2018). Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study. European Archives of Psychiatry and Clinical Neuroscience. 270(1). 3–10. 31 indexed citations
12.
Blin, Patrick, C. Dureau‐Pournin, Abdelilah Abouelfath, et al.. (2017). Bénéfice–risque des anticoagulants oraux directs comparés aux antivitamines K dans la fibrillation auriculaire non valvulaire : cohorte ENGEL de plus de 100 000 patients issus du Sniiram. Revue d Épidémiologie et de Santé Publique. 65. S111–S111. 1 indexed citations
13.
Bezin, Julien, Olaf H. Klungel, R. Lassalle, et al.. (2017). Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real‐Life Setting. Clinical Pharmacology & Therapeutics. 103(6). 1038–1046. 5 indexed citations
14.
Blin, Patrick, Gérard de Pouvourville, Yves Cottin, et al.. (2017). Comparative Effectiveness And Medical Cost of Dabigatran Versus Vitamin K Antagonists From Engel 2: A French Nationwide Cohort Of 100,000 Patients With Non-Valvular Atrial Fibrillation. Value in Health. 20(9). A608–A609. 1 indexed citations
15.
Blin, Patrick, C. Dureau‐Pournin, R. Lassalle, et al.. (2016). Outcomes, Health Care Resources Use, And Costs In Patients With Post-Myocardial Infarction: The Horus Cohort Study In The Egb French Claims And Hospital Database. Value in Health. 19(3). A16–A16. 2 indexed citations
16.
Blin, Patrick, C. Dureau‐Pournin, R. Lassalle, et al.. (2015). A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. British Journal of Clinical Pharmacology. 81(3). 569–578. 19 indexed citations
17.
Dureau‐Pournin, C., Jean‐Michel Pedespan, C. Droz‐Perroteau, et al.. (2013). Continuation rates of levetiracetam in children from the EULEVp cohort study. European Journal of Paediatric Neurology. 18(1). 19–24. 4 indexed citations
18.
Bezin, Julien, Alexandre Pariente, R. Lassalle, et al.. (2013). Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. European Journal of Clinical Pharmacology. 70(4). 429–436. 35 indexed citations
19.
Blin, Patrick, R. Lassalle, C. Dureau‐Pournin, et al.. (2012). Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 55(3). 644–653. 70 indexed citations
20.
Droz‐Perroteau, C., C. Dureau‐Pournin, Hervé Vespignani, et al.. (2010). The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year. British Journal of Clinical Pharmacology. 71(1). 121–127. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoyang Liao Breakdown of academic impact, for papers by Natsumi Ueda Breakdown of academic impact, for papers by Siin Kim Breakdown of academic impact, for papers by Ryogo Umetsu Breakdown of academic impact, for papers by Luis Carlos Saiz Breakdown of academic impact, for papers by Simone Y. Loo Breakdown of academic impact, for papers by Yamato Kato Breakdown of academic impact, for papers by Michele A. Faulkner Breakdown of academic impact, for papers by RL Sacco Breakdown of academic impact, for papers by D Schröder-Bernhardi
Rankless by CCL
2026